Aurobindo Pharma is currently trading at Rs. 188.25, up by 1.20 points or 0.64% from its previous closing of Rs. 187.05 on the BSE.
The scrip opened at Rs. 187.95 and has touched a high and low of Rs. 188.75 and Rs. 184.00 respectively. So far 66,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 201.40 and a 52 week low of Rs. 83.35.
Last one week high and low of the scrip stood at Rs. 197.35 and Rs. 181.10 respectively. The current market cap of the company is Rs. 5,480.00 crore.
The promoters holding in the company stood at 54.76% while Institutions and Non-Institutions held 29.33% and 15.91% respectively.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market the earlier tentatively approved Abacavir Tablets USP 300mg (ANDA 077844) and is ready for launch. The product has been approved out of Unit III formulations facility in Hyderabad, India.
Abacavir Tablets USP 300mg is the generic equivalent of ViiV Healthcare Company’s Ziagen Tablets 300mg and is indicated as part of antiretroviral (ARV) combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. The annual sale of the product is approximately $88 million.
Aurobindo now has a total of 167 ANDA approvals 141 final approvals including 2 from Aurolife Pharma LLC and 26 tentative approvals from USFDA.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1746.05 |
Dr. Reddys Lab | 1334.15 |
Cipla | 1438.80 |
Lupin | 2154.05 |
Zydus Lifesciences | 974.30 |
View more.. |